Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 31;95(8):639–643. doi: 10.1111/j.1349-7006.2004.tb03322.x

Tumorigenesis facilitated by Pten deficiency in the skin: Evidence of p53‐Pten complex formation on the initiation phase

Nobuyasu Komazawa 1, Akira Suzuki 2, Shigetoshi Sano 3, Kyoji Horie 1,4, Nariaki Matsuura 5, Tak Wah Mak 6, Toru Nakano 7, Junji Takeda 1,4, Gen Kondoh 1,✉
PMCID: PMC11159272  PMID: 15298725

Abstract

Pten, a tumor suppressor gene, is mutated in various human cancers and in hereditary cancer syndromes, such as Cowden disease. We have previously developed a knockout mouse in which Pten is specifically disrupted in the skin, resulting in hyperproliferation and spontaneous tumorigenesis of the skin keratinocytes. In this study, we further clarified the effects of Pten deficiency in tumorigenesis, by using a two‐step model in intact skin of Pten knockout mouse. Although the conventional protocol requires serial exposures to DMBA and TPA, mice deficient for Pten developed skin papilloma within 6 weeks after a single exposure to DMBA, indicating that loss of Pten has a tumor‐promoting effect. Serial exposure to DMBA‐TPA ointments produced 10‐fold more papillo mas in the skin of knockout mice than in the wild‐type counterpart, suggesting an increased rate of initiation. Therefore, we precisely examined the effect of DMBA. This treatment was highly apoptotic in wild‐type mice, whereas the number of apop totic cells was diminished in Pten‐deficient skin. Moreover, primary keratinocytes isolated from Pten‐deficient mice were also resistant to the apoptotic effect of DMBA. The status of p53, Pten proteins and downstream targets of p53, such as p21, 14–3–3a, and Reprimo, were also examined, and we found that accumulation of p53 protein and up‐regulation of p53 targets were delayed in Pten‐knockout skin. These observations suggest that Pten is involved in rapid recruitment of p53 in the tumor initiation phase.

Abbreviations:

DMBA

7,12‐dimethylbenz(a)anthracene

TPA

12‐O‐tetrade‐ canoylphorbol‐13‐acetate

PKB

protein kinase B

References

  • 1. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943–7. [DOI] [PubMed] [Google Scholar]
  • 2. Marsh DJ, Dahia PL, Zheng Z et al. Germline mutations in PTEN are present in Bannayan‐Zonana syndrome. Nat Genet 1997; 16: 333–4. [DOI] [PubMed] [Google Scholar]
  • 3. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet, 1997; 16: 64–7. [DOI] [PubMed] [Google Scholar]
  • 4. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5‐tris‐phosphate. J Biol Chem. 1998; 273: 13375–8. [DOI] [PubMed] [Google Scholar]
  • 5. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt‐dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29–39. [DOI] [PubMed] [Google Scholar]
  • 6. Kiguchi K, Beltran L, Rupp T et al. Altered expression of epidermal growth factor receptor ligands in tumor promoter‐treated mouse epidermis and in primary mouse skin tumors induced by an initiation‐promotion protocol. Mol Carcinog 1998; 22: 73–83. [PubMed] [Google Scholar]
  • 7. DiGiovanni J, Kiguchi K, Frijhoff A et al. Deregulated expression of insulin‐like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc NatlAcadSci USA 2000; 97: 3455–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Ali IU. Gatekeeper for endometrium: the PTEN tumor suppressor gene. J Natl Cancer Inst 2000; 92: 861–3. [DOI] [PubMed] [Google Scholar]
  • 9. Suzuki A, de la Pompa JL, Stambolic V et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169–78. [DOI] [PubMed] [Google Scholar]
  • 10. Suzuki A, Itami S, Ohishi M et al. Keratinocyte‐specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 2003; 63: 674–81. [PubMed] [Google Scholar]
  • 11. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of onco‐genic signaling. Cancer Treat Res 2003; 115: 145–67. [PubMed] [Google Scholar]
  • 12. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor‐oncopro‐tein network. Trends Biochem Sci 2002; 27: 462–7. [DOI] [PubMed] [Google Scholar]
  • 13. Stambolic V, MacPherson D, Sas D et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317–25. [DOI] [PubMed] [Google Scholar]
  • 14. Freeman DJ, Li AG, Wei G et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase‐dependent and ‐independent mechanisms. Cancer Cell 2003; 3: 117–30. [DOI] [PubMed] [Google Scholar]
  • 15. Suzuki A, Yamaguchi MT, Ohteki T et al. T cell‐specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523–34. [DOI] [PubMed] [Google Scholar]
  • 16. Tarutani M, Itami S, Okabe M et al. Tissue‐specific knockout of the mouse Pig‐a gene reveals important roles for GPI‐anchored proteins in skin development. Proc Natl Acad Sci USA 1997; 94: 7400–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992; 54: 63–128. [DOI] [PubMed] [Google Scholar]
  • 18. Umeda J, Sano S, Kogawa K et al. In vivo cooperation between Bcl‐xL and the phosphoinositide 3‐kinase‐Akt signaling pathway for the protection of epidermal keratinocytes from apoptosis. FASEB J 2003; 17: 610–20. [DOI] [PubMed] [Google Scholar]
  • 19. Rodriguez‐Villanueva J, Greenhalgh D, Wang, XJ et al. Human keratin‐l.bcl‐2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation. Oncogene 1998; 16: 853–63. [DOI] [PubMed] [Google Scholar]
  • 20. Manoharan K, Kinder D, Banerjee MR. DMBA induced DNA damage and repair in mammary epithelial cells in vitro measured by a nick translation assay. Cancer Biochem. Biophys 1987; 9: 127–32. [PubMed] [Google Scholar]
  • 21. Ise K, Nakamura K, Nakao K et al. Targeted deletion of the H‐ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 2000; 19: 2951–6. [DOI] [PubMed] [Google Scholar]
  • 22. Khosravi R, Maya R, Gottilieb T et al. Rapid ATM‐dependent phospholyla‐tion of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 14973–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Yamasaki L. Role of the Rb tumor suppressor in cancer. Cancer Treat Res 2003; 115: 209–39. [DOI] [PubMed] [Google Scholar]
  • 24. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor‐oncopro‐tein network. Trends Biochem. Sci 2002; 27: 462–7. [DOI] [PubMed] [Google Scholar]
  • 25. Chene P. Inhibiting the p53‐MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102–9. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES